Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 16, 2010

Helicon to Exploit Sapient’s Structural Biology Expertise to Expedite Lead Design

  • Helicon Therapeutics is tapping into Sapient Discovery’s structural biology expertise to unravel the 3-D structures of specific drug targets. Through the collaboration, the firm will provide Helicon with a complete array of x-ray crystallography and modeling services including cloning, expression, protein purification, and co-crystal structure determination.

    Helicon is focused on the discovery of therapeutics to treat disorders of cognition through an understanding of the genetic basis of long-term memory formation. The firm says that structural data obtained from Sapient will help expedite structure-based lead design and optimization.

    Sapient Discovery is exploiting its structural design expertise, large-scale structural databases, and leading-edge computational methodologies to help its partners accelerate the drug discovery and drug optimization processes.

    In addition to structure determination services the company has developed its Genes To Leads™ service for accelerating lead discovery and target validation as well as the Fragments to Leads™ platform for generating novel lead molecules with x-ray crystallography and fragment libraries. StructureBank™ is a database for the large-scale comparative analysis of protein targets and antitargets.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »